NCT02445352View on ClinicalTrials.gov

Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

379

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

March 31, 2015

Conditions
Primary Hypercholesterolemia
Interventions
DRUG

Rosuvastatin 5mg

DRUG

DP-R207 5/10mg

DRUG

Rosuvastatin 10mg

DRUG

DP-R207 10/10mg

DRUG

Rosuvastatin 20mg

DRUG

DP-R207 20/10mg

DRUG

Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)

DRUG

Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)

DRUG

Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)

Trial Locations (1)

120-752

Severance Hospital, Seodaemun-gu

Sponsors

Lead Sponsor

Alvogen Korea
All Listed Sponsors
lead

Alvogen Korea

INDUSTRY